Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet

By In The News
November 13, 2020 in The Headlines

Followers 0

Reply to this topic

Recommended Posts

In The News

Posted November 13, 2020

- Share

Posted November 13, 2020

NEWTON, Mass., Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON (Bortezomib, Selinexor and Dexamethasone) study evaluating XPOVIO...

View the full article

Quote

Link to comment

Share on other sites

Reply to this topic...

× Pasted as rich text. Paste as plain text instead

Only 75 emoji are allowed.

× Your link has been automatically embedded. Display as a link instead

× Your previous content has been restored. Clear editor

× You cannot paste images directly. Upload or insert images from URL.

Insert image from URL

Followers 0

Go to topic listing

Most Contributions
1. In The News
  201557
2. Jaydee
  13894
3. Kip Powick
  11834
4. deicer
  10842
5. dagger
  9572
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  251.4k
- Total Posts
  
  523.7k

Sign In

Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet

Recommended Posts

In The News

Link to comment

Share on other sites

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support